NCT00382512已完成1 期
A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Mean concentrations of anti-<phi>X174 antibodies in the FU period 2 weeks after the FU Day 70 vaccinations in Group A compared with mean antibody concentrations 2 weeks after the Treatment Day 63 vaccination in Group C
研究概览
简要总结
This is a Phase I, randomized, placebo-controlled, single blind, parallel group, single-center study designed to evaluate immune responses during and after administration of 12 weekly SC doses of 1.0 mg/kg efalizumab in subjects with moderate plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Plaque psoriasis covering 8%-15% of the total BSA
- •Diagnosis of plaque psoriasis for at least 6 months
- •Body weight of ≤140 kg
- •18 to 65 years old
- •For women of childbearing potential and men who may father children, use of an acceptable method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study (the following methods of contraception are acceptable: condom; abstinence; oral, implantable or injectable contraceptives by the sexual partner; IUD, female condom, diaphragm with spermicide, cervical cap; a sterile sexual partner)
- •Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study
- •History of tetanus vaccination
排除标准
- •Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- •History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies or fusion proteins that contain an Ig Fc region
- •Clinically significant psoriasis exacerbation during screening or at the time of enrollment
- •History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- •History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •Seropositivity for human immunodeficiency virus (HIV)
- •Pregnancy or lactation
- •White blood cell (WBC) count <4000/uL or >14,000/uL
- •Seropositivity for hepatitis B or C virus
- •Hepatic enzymes ≥3 times the upper limit of normal
- •Tetanus or pneumococcal vaccination during the 6 months prior to the start of the study (Treatment Day 0) or failure to complete a primary series of tetanus immunizations
- •Known hypersensitivity reaction to tetanus or diphtheria toxoid
- •Known hypersensitivity to any of the administered vaccinations or their components
- •History of active tuberculosis (TB) or currently undergoing treatment for TB
- •Positive purified protein derivative (PPD) (tuberculin) testing at screening (as defined by CDC Guidelines, see Appendix C for test assessment criteria and listing of high-risk groups)
- •Presence of malignancy within the past 5 years, including lymphoproliferative disorders
- •Treatment with efalizumab (anti-CD11a) within the last 12 months
- •Previous administration of <phi>X174
- •Diagnosis of hepatic cirrhosis, regardless of cause or severity
- •Serum creatinine ≥2 times the upper limit of normal
- •Hospital admission for cardiac disease, stroke, or pulmonary disease within the last year
- •History of substance abuse within the last 5 years as judged by the Principal Investigator
- •Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug
- •Systemic therapy for psoriasis (Screening Day -28 through FU Day 98)
- •Systemic immunosuppressive drugs for any indications (Screening Day -28 through FU Day 98)
- •Live virus or bacteria vaccines other than protocol specified (Screening Day -14 through Treatment Day 84)
- •Other vaccines or allergy desensitization (must be scheduled at least 14 days prior to Treatment Day 0 or after FU Day 98)
- •Other experimental drugs or treatments (within 90 days or five half-lives, whichever is longer, prior to Treatment Day 0 and through FU Day 98)
- •<beta>-Blockers, angiotensin-converting enzyme (ACE) inhibitors, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant between Screening Day -28 and Treatment Day 84)
结局指标
主要结局
Mean concentrations of anti-<phi>X174 antibodies in the FU period 2 weeks after the FU Day 70 vaccinations in Group A compared with mean antibody concentrations 2 weeks after the Treatment Day 63 vaccination in Group C
Mean concentrations of anti-<phi>X174 antibodies in the FU period 2 weeks after the FU Day 70 vaccination in Group B compared with mean antibody concentrations 2 weeks after the Treatment Day 63 vaccination in Group C.
次要结局
- Characterization of mean concentrations of anti-<phi>X174 antibodies 2 weeks after the FU Day 42 vaccination in Group A compared with mean antibody concentrations 2 weeks after the Treatment Day 35 vaccination in Group C
- Characterization of mean concentrations of anti-<phi>X174 antibodies 2 weeks after the FU Day 42 vaccination in Group B compared with mean antibody concentrations 2 weeks after the Treatment Day 35 vaccination in Group C
- Characterization of mean anti-<phi>X174 concentrations 2 and 4 weeks after the first and 2 and 4 weeks after the second <phi>X174 vaccinations during efalizumab treatment (Group A) compared with placebo (Group C)
- Characterization of mean concentrations of anti-tetanus IgG during treatment with efalizumab compared with placebo, representing a secondary humoral immune response
- Characterization of anti-pneumococcal antibody concentrations on FU Day 70 after pneumococcal vaccination on FU Day 42 compared with placebo
- Percentage of subjects with positive skin test reactions to tetanus and Candida-recall antigens on FU Day 77 after washout from efalizumab compared with baseline.
研究者
相似试验
已完成
1 期
AZD2423 Single Ascending Dose Study in Healthy Japanese SubjectsHealthy VolunteerNCT00970775AstraZeneca32
已完成
1 期
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy AdultsHealthy Volunteers - Male and FemaleNCT06649942Kaken Pharmaceutical40
已完成
1 期
Tezepelumab Phase 1 PK Study in Healthy Chinese SubjectsHealthy SubjectsNCT04362410AstraZeneca48
撤回
1 期
Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA PatientsParkinson's DiseaseNCT02758730Affiris AG
已完成
1 期
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy SubjectsSARS-CoV-2 InfectionNCT05017168Celltrion24